Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib for lichen planus
IRCT20150825023753N31Phase 3Recruiting
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of upadacitinib in lichen planus (LP) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Lichen Planus Activity and Damage Index. Started Oct 2026; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
lichen planus (LP)
Beyond the preview
Go deeper on IRCT20150825023753N31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150825023753N31.